Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2015; 7(9): 148-152
Published online Sep 15, 2015. doi: 10.4251/wjgo.v7.i9.148
Intrahepatic therapy for liver-dominant metastatic colorectal cancer
Kerlijne De Groote, Hans Prenen
Kerlijne De Groote, Hans Prenen, Department of Gastroenterology, University Hospitals Leuven, B-3000 Leuven, Belgium
Author contributions: De Groote K and Prenen H contributed equally to this work.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Hans Prenen, MD, Professor of Medicine, Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Telephone: +32-16-340238 Fax: +32-16-344419
Received: March 21, 2015
Peer-review started: March 22, 2015
First decision: July 1, 2015
Revised: July 6, 2015
Accepted: July 29, 2015
Article in press: August 3, 2015
Published online: September 15, 2015
Core Tip

Core tip: Thanks to the increased chemotherapeutic options in patients with metastatic colorectal cancer (mCRC), the overall survival has significantly improved the last decade. Liver failure is a common cause of death in mCRC with liver metastases. Therefore in these patients locoregional treatment is a valuable treatment option in order to increase survival. In this review we provide insights on the published literature.